Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

IXICO makes two boardroom changes

Going forward, IXICO will have two executive directors and three non-execs

Medical technology company IXICO PLC (LON:IXI) has made two top-level changes.

Chief financial officer Grant Nash, appointed to the role in April, joins the board with immediate effect.

WATCH: IXICO CFO Grant Nash joins board and discusses 'strong' 2019 performance

Tim Sharpington, the company’s senior independent director for the last six years, will step down at the end of the current financial year.

His role as senior independent director and head of the remuneration committee will be assumed by Mark Warne.

Following the changes, IXICO will have two executive directors and three non-execs.

Chief executive Giulio Cerroni said: "Grant's appointment to the board reflects the substantial contribution he has already made to IXICO since his appointment as CFO.

“He has brought strong financial leadership skills combined with a deep appreciation of operational excellence at a time of significant revenue growth and an accelerated path to profitability.

“Separately, I would like to thank Tim for all his counsel and guidance to me personally since I joined the company and wish him well for the future."

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK